The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | Off-the-shelf cellular therapy approaches in myeloma: allo and in vivo CARs
In this video, Karlo Perica, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the development of off-the-shelf cellular therapy approaches in multiple myeloma (MM), namely allogeneic and in vivo strategies, highlighting how these may overcome the limitations of traditional autologous CAR T-cell therapies. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In myeloma, we’ve been very lucky that autologous CAR T-cells, CAR T-cells made from the patient’s own cells, have been extremely effective. And we’re now seeing with the product cilta-cel, five-year durable survival and potentially even a cure. So that’s fantastic. But we’re still limited by the cost and complexity of autologous cell therapy...
In myeloma, we’ve been very lucky that autologous CAR T-cells, CAR T-cells made from the patient’s own cells, have been extremely effective. And we’re now seeing with the product cilta-cel, five-year durable survival and potentially even a cure. So that’s fantastic. But we’re still limited by the cost and complexity of autologous cell therapy. It costs hundreds of thousands of dollars. Patients have to wait weeks, if not months, for their cells to arrive. So we’re really looking for alternative strategies that are available immediately off-the-shelf.
There’s a number of these. The two biggest in the CAR T-cell world are so-called allogeneic cell therapies and in vivo cell therapies. So allogeneic cell therapies are donor-derived. That means they come usually from a healthy donor. There’s also some research in stem cell approaches. And they really have the advantage that they can be made from young healthy donors with really functionally effective T-cells.
And now increasingly you have interest in in vivo CAR T-cells which are CAR T-cells that are actually made inside the patient’s body and can be delivered via lipid nanoparticle or viral approaches and be made right then and there inside the patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
